Literature DB >> 75740

Studies with bleomycin and misonidazole on aerated and hypoxic cells.

L Roizin-Towle, E J Hall.   

Abstract

Bleomycin is a chemotherapuetic drug used primarily in the treatment of squamous-cell carcinoma, while misonidazole is an effective radiosensitizer and potent cytotoxic agent selectively affecting hypoxic cells. V79 Chinese hamster cells were used to investigate the cytotoxicity of bleomycin (BLM) under aerated and hypoxic conditions as a function of drug concentration. At a lowered temperature of 17.5 degrees C, or at an elevated temperature of 42.5 degrees C, hypoxic cells are more sensitive to killing by BLM than aerated cells. At either of these temperatures, progression through the cell cycle is inhibited. However, at 37.5 degrees C, mimicking a clinical situation, the sensitivies are reversed, and hypoxic cells are appreciably more resistant. Although many factors are involved, the major reason for this is that aerated cells are cycling while hypoxic cells are not. Aerated cells can progress into phases of the cell cycle where they are more sensitive to killing by BLM. Misoinidazole (=Ro-07-0582) was used in combination with BLM, since its mode of action has been shown to be psecific for killing hypoxic cells. It concomitant use with BLM could be of potential use in chemotherapy when confronted with the hypoxic cell component of solid tumours.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 75740      PMCID: PMC2009591          DOI: 10.1038/bjc.1978.34

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Hypoxic sensitizers: radiobiological studies at the cellular level.

Authors:  E J Hall; L Roizin-Towle
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

Review 2.  Chemical radiosensitization of hypoxic cells.

Authors:  G E Adams
Journal:  Br Med Bull       Date:  1973-01       Impact factor: 4.291

3.  Effects of bleomycin on progression through the cell cycle of mouse L-cells.

Authors:  M Watanabe; Y Takabe; T Katsumata; T Terasima
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

4.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

5.  Cell survival and repair of plateau-phase cultures after chemotherapy--relevance to tumor therapy and to the in vitro screening of new agents.

Authors:  G R Ray; G M Hahn; M A Bagshaw; S Kurkjian
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

6.  Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure.

Authors:  G M Hahn; G R Ray; L F Gordon; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

7.  The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro.

Authors:  S C Barranco; R M Humphrey
Journal:  Cancer Res       Date:  1971-09       Impact factor: 12.701

8.  Nitroheterocyclic drugs as selective radiosensitizers of hypoxic mammalian cells.

Authors:  J D Chapman; A P Reuvers; J Borsa; J S Henderson; R D Migliore
Journal:  Cancer Chemother Rep       Date:  1974 Jul-Aug

9.  Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation.

Authors:  G M Hahn; J Braun; I Har-Kedar
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

10.  Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug.

Authors:  P W Sheldon; J L Foster; J F Fowler
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

View more
  25 in total

1.  5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.

Authors:  Z Bardakji; J Jolivet; Y Langelier; J G Besner; J Ayoub
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Sectional analysis of tumor colony growth in the soft-agar assay: effects of oxygen.

Authors:  D Fan; S Fan; L R Morgan
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

4.  Differential survival of cell subpopulations in spheroids after treatment with bleomycin.

Authors:  D Tobüren
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

5.  Modulation of bleomycin cytotoxicity.

Authors:  C W Moore
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Modifiers of free radicals inhibit in vitro the oncogenic actions of x-rays, bleomycin, and the tumor promoter 12-O-tetradecanoylphorbol 13-acetate.

Authors:  C Borek; W Troll
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Heat shock phenomena in Aspergillus nidulans. II. Combined effect of heat and bleomycin to heat shock protein synthesis, survival rate and induction of mutations.

Authors:  G Stephanou; N A Demopoulos
Journal:  Curr Genet       Date:  1987       Impact factor: 3.886

8.  Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin.

Authors:  T Yamauchi; T A Raffin; P Yang; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  The importance of understanding the infectious microenvironment.

Authors:  Thomas Bjarnsholt; Marvin Whiteley; Kendra P Rumbaugh; Philip S Stewart; Peter Ø Jensen; Niels Frimodt-Møller
Journal:  Lancet Infect Dis       Date:  2021-09-07       Impact factor: 71.421

10.  The relationship between tissue oxygenation and redox status using magnetic resonance imaging.

Authors:  Fuminori Hyodo; Ryan M Davis; Emi Hyodo; Shingo Matsumoto; Murali C Krishna; James B Mitchell
Journal:  Int J Oncol       Date:  2012-09-24       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.